Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases
– Funding will enable lead candidates CTX114 and CTX203 for AMD to enter clinical trialsin thenext year JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, announced today an…